ESAB Corporation delivered a strong second quarter in 2025, with sales reaching $716 million. The company achieved a record core adjusted EBITDA margin of 20.4% and reported diluted EPS of $1.12, with core adjusted EPS at $1.36. Strategic acquisitions in medical gas control and welding equipment further strengthened its market position, leading to an upward revision of its full-year 2025 guidance.
ESAB reported second quarter sales of $716 million, a 1% increase on a reported basis compared to the prior year.
The company achieved a record core adjusted EBITDA margin of 20.4%, reflecting consistent performance and resilience.
Diluted earnings per share (EPS) from continuing operations were $1.12, and core adjusted diluted EPS was $1.36.
ESAB completed two Gas Control acquisitions (DeltaP and Aktiv) and signed one Fab Tech acquisition (EWM), advancing its compounder strategy.
ESAB Corporation has raised its full-year 2025 outlook, anticipating higher total core sales growth, increased core adjusted EBITDA, and improved core adjusted EPS.
Visualization of income flow from segment revenue to net income